BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34000802)

  • 1. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
    Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
    J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
    Xie X; Liu J; Wang X
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
    Vavřina Z; Perlíková P; Milisavljević N; Chevrier F; Smola M; Smith J; Dejmek M; Havlíček V; Buděšínský M; Liboska R; Vaneková L; Brynda J; Boura E; Řezáčová P; Hocek M; Birkuš G
    J Med Chem; 2022 Oct; 65(20):14082-14103. PubMed ID: 36201304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
    Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
    Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structures of porcine STING
    Cong X; Yuan Z; Du Y; Wu B; Lu D; Wu X; Zhang Y; Li F; Wei B; Li J; Wu J; Xu S; Wang J; Qi J; Shang G; Gu L
    J Biol Chem; 2019 Jul; 294(30):11420-11432. PubMed ID: 31167783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
    Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
    ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of Original Cyclic Dinucleotide Analogues Using the Sulfo-click Reaction.
    Amador R; Vasseur JJ; Birkuš G; Bignon E; Monari A; Clavé G; Smietana M
    Org Lett; 2024 Feb; 26(4):819-823. PubMed ID: 38236576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
    Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
    Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I
    Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STING activation in cancer immunotherapy.
    Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
    Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING Activation and its Application in Immuno-Oncology.
    Lian Y; Duffy KJ; Yang J
    Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
    Dejmek M; Brazdova A; Otava T; Polidarova MP; Klíma M; Smola M; Vavrina Z; Buděšínský M; Dračínský M; Liboska R; Boura E; Birkuš G; Nencka R
    Eur J Med Chem; 2023 Nov; 259():115685. PubMed ID: 37567057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.
    Moore E; Clavijo PE; Davis R; Cash H; Van Waes C; Kim Y; Allen C
    Cancer Immunol Res; 2016 Dec; 4(12):1061-1071. PubMed ID: 27821498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy.
    Waters CM
    Open Biol; 2021 Dec; 11(12):210277. PubMed ID: 34905701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
    Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.